FDA approves first factor XIa inhibitor to cut secondary stroke risk

Key takeaways

• Sunharbo 50 mg daily lowered ischemic-stroke recurrence by 26% versus placebo in the OCEANIC-STROKE trial of 12,327 adults.
• Major-bleeding rates were comparable overall, yet patients over 75 experienced higher bleeding, especially in the first 90 days.
• The drug cannot be co-administered with combined P-gp and strong CYP3A4 inducers and is contraindicated in moderate-to-severe hepatic impairment.

The U.S. Food and Drug Administration’s approval of Sunharbo (asundexian) marks the first use of a factor XIa (FXIa) inhibitor for secondary stroke prevention. The decision follows a phase 3 trial that showed a 26 percent reduction in recurrent ischemic stroke when the drug was added to standard antiplatelet therapy.

Trial evidence and clinical impact

The OCEANIC-STROKE study enrolled 12,327 adults who had suffered a recent mild-to-moderate non-cardioembolic ischemic stroke (NIH Stroke Scale ≤15) or a high-risk transient ischemic attack. Participants were randomized within 72 hours of symptom onset to receive Sunharbo 50 mg once daily or placebo, with all patients continuing antiplatelet therapy. Over a median follow-up of 14.2 months, the Sunharbo arm experienced a statistically significant 26 percent relative risk reduction in ischemic stroke compared with placebo.

Safety profile and use restrictions

Overall major-bleeding rates were similar between the two groups, but subgroup analysis revealed an increased bleeding signal in patients older than 75 years and during the first 90 days of treatment. Gastrointestinal bleeding occurred more frequently with Sunharbo, and diarrhea was reported in 3 percent or more of treated patients. The label advises against co-administration with combined P-gp and strong CYP3A4 inducers—such as carbamazepine—because they may diminish drug exposure. Sunharbo is also contraindicated in patients with moderate or severe hepatic impairment and is not approved for stroke prevention in atrial-fibrillation.

Operational considerations for health systems

Hospitals and health systems must integrate new prescribing rules into electronic health record (EHR) order sets. Alerts should flag patients over 75 years, highlight the 90-day heightened bleeding window, and block concurrent prescriptions of contraindicated inducers. Pharmacy teams need to educate clinicians on the drug’s washout requirements—at least 24 hours before elective surgery or invasive procedures and after thrombolytic therapy.

Market and regulatory context

The FDA granted Sunharbo Fast Track and Priority Review designations, underscoring the agency’s recognition of the unmet need for safer antithrombotic options. Bayer HealthCare Pharmaceuticals Inc., based in Whippany, N.J., received the approval, positioning the company at the forefront of the emerging FXIa inhibitor class.

Next steps for leaders

Implementing Sunharbo will require a balance between its stroke-preventive benefit and the modestly elevated bleeding risk in older patients. Decision makers should assess their patient populations for eligibility, adjust care pathways to accommodate the drug’s specific contraindications, and monitor outcomes closely during the early treatment window.

Action plan: 1. Identify eligible patients – Use stroke registries to flag adults with recent non-cardioembolic ischemic stroke or high-risk TIA who are on antiplatelet therapy. Trade-off: broader inclusion captures more benefit but may increase exposure to bleeding in marginal candidates. 2. Update EHR order sets – Embed dosage, contraindication checks, and timing alerts for surgery or thrombolysis. Trade-off: development effort versus reduced prescribing errors. 3. Educate prescribers and pharmacists – Conduct targeted training on the 75-year age threshold, drug-interaction cautions, and hepatic-impairment exclusions. Trade-off: resource allocation versus improved safety compliance. 4. Monitor real-world outcomes – Track ischemic-stroke recurrence and bleeding events in the first 90 days to refine patient selection. Trade-off: data-collection burden versus ability to calibrate use protocols.